(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 29 March 2001 (29.03.2001)

PCT

(10) International Publication Number WO 01/21645 A2

(51) International Patent Classification7:

C07K 14/00

(21) International Application Number: PCT/GB00/03568

(22) International Filing Date:

18 September 2000 (18.09.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

GB9921938.8

17 September 1999 (17.09.1999)

- (71) Applicant (for all designated States except US): THE UNIVERSITY OF YORK [GB/GB]; Heslington Hall, York YO10 5DD (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ANTSON, Alfred [GB/GB]; Department of Chemistry, University of York, York YO10 5DD (GB). MAITLAND, Norman [GB/GB]; Department of Biology, University of York, York YO10 5DD (GB).

- HARRISON GODDARD FOOTE; Tower House, Merrion Way, Leeds LS2 8PA (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TARGET FOR ANTIVIRAL THERAPY

(57) Abstract: A crystallised molecular complex of an E2 N-terminal module (E2NT) dimer protein or homologue thereof, that comprises residues vital for viral transcription and/or replication. The invention also provides for the use of the dimer protein and interactions at its dimerisation surface in rationalised antiviral drug design.